Key result
Recent observations support the hypothesis that anthracycline and TKI-induced cardiotoxicity may involve the impairment of the resident cardiac stem cell pool responsible for cardiac repair.
Why the study?
Does anti-cancer therapy (anthracyclines and TKIs) induce cardiotoxicity by targeting resident cardiac stem cells in cancer patients?
Population
Childhood and adult cancer patients receiving anti-cancer therapy
Design
Review
Authors
Loading...
Does not alter cardiotoxicity management; leaves open whether targeting resident cardiac stem cells could prevent anthracycline- or TKI-induced damage.
Does anti-cancer therapy (anthracyclines and TKIs) induce cardiotoxicity by targeting resident cardiac stem cells in cancer patients?
This review proposes a novel hypothesis that cancer treatment-induced cardiotoxicity may be a cardiac stem cell disease, opening potential new therapeutic avenues for prevention.
Prezioso et al. (2010) conducted a review in Cancer treatment-induced cardiotoxicity. Anti-cancer therapy (Anthracyclines and TKIs) was evaluated. Recent observations support the hypothesis that anthracycline and TKI-induced cardiotoxicity may involve the impairment of the resident cardiac stem cell pool responsible for cardiac repair.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: